Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.

Cancers (Basel) 2018 Jun 15;10(6). Epub 2018 Jun 15.

Department of Oncology, University of Calgary, 1331 29 Street NW, Calgary, AB T2N 4N2, Canada.

As the current efficacy of oncolytic viruses (OVs) as monotherapy is limited, exploration of OVs as part of a broader immunotherapeutic treatment strategy for cancer is necessary. Here, we investigated the ability for immune checkpoint blockade to enhance the efficacy of oncolytic reovirus (RV) for the treatment of breast cancer (BrCa). In vitro, oncolysis and cytokine production were assessed in human and murine BrCa cell lines following RV exposure. Furthermore, RV-induced upregulation of tumor cell PD-L1 was evaluated. In vivo, the immunocompetent, syngeneic EMT6 murine model of BrCa was employed to determine therapeutic and tumor-specific immune responses following treatment with RV, anti-PD-1 antibodies or in combination. RV-mediated oncolysis and cytokine production were observed following BrCa cell infection and RV upregulated tumor cell expression of PD-L1. In vivo, RV monotherapy significantly reduced disease burden and enhanced survival in treated mice, and was further enhanced by PD-1 blockade. RV therapy increased the number of intratumoral regulatory T cells, which was reversed by the addition of PD-1 blockade. Finally, dual treatment led to the generation of a systemic adaptive anti-tumor immune response evidenced by an increase in tumor-specific IFN-γ producing CD8⁺ T cells, and immunity from tumor re-challenge. The combination of PD-1 blockade and RV appears to be an efficacious immunotherapeutic strategy for the treatment of BrCa, and warrants further investigation in early-phase clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10060205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025420PMC
June 2018
57 Reads

Publication Analysis

Top Keywords

pd-1 blockade
12
oncolysis cytokine
8
breast cancer
8
brca cell
8
efficacy oncolytic
8
cytokine production
8
tumor cell
8
immunotherapeutic strategy
8
immune checkpoint
8
oncolytic reovirus
8
treatment
5
brca
5
expression pd-l1
4
treated mice
4
mice enhanced
4
enhanced pd-1
4
cell expression
4
upregulated tumor
4
survival treated
4
reduced disease
4

Similar Publications